Department of Pathology and Laboratory Medicine.
Lunenfeld-Tanenbaum Research Institute, Sinai Health System.
Am J Surg Pathol. 2022 Oct 1;46(10):1340-1351. doi: 10.1097/PAS.0000000000001920. Epub 2022 May 25.
Tumor budding (TB) and poorly differentiated clusters (PDCs) are powerful prognostic factors in colorectal cancer (CRC). Despite their morphologic and biological overlap, TB and PDC are assessed separately and are distinguished by an arbitrary cutoff for cell cluster size. This cutoff can be challenging to apply in practice and its biological significance remains unclear. We developed a novel scoring system that incorporates TB and PDC into a single parameter ("Combined Score"; CS), eliminating the need for such cutoffs and allowing the prognostic value of PDC to be captured alongside TB. In a cohort of 481 stage I-III CRC resections, CS was significantly associated with American Joint Committee on Cancer (AJCC) stage, T-stage, N-stage, histologic grade, tumor deposits, lymphovascular invasion, and perineural invasion ( P <0.0001). In addition, CS was significantly associated with decreased 5-year recurrence-free survival, overall survival, and disease-specific survival ( P <0.0001). TB and PDC showed similar associations with oncologic outcomes, with hazard ratios consistently lower than for CS. The association between CS and oncologic outcomes remained significant in subgroup analyses stratified by AJCC stage, anatomic location (rectum/colon) and neoadjuvant therapy status. On multivariable analysis, CS retained its significant association with oncologic outcomes ( P =0.0002, 0.005, and 0.009) for recurrence-free survival, disease-specific survival, and overall survival, respectively. In conclusion, CS provides powerful risk stratification in CRC which is at least equivalent to that of TB and PDC assessed individually. If validated elsewhere, CS has practical advantages and a biological rationale that may make it an attractive alternative to assessing these features separately.
肿瘤芽(TB)和低分化簇(PDC)是结直肠癌(CRC)强有力的预后因素。尽管它们在形态和生物学上有重叠,但 TB 和 PDC 是分开评估的,其细胞簇大小的界限是任意的。这个界限在实际应用中具有挑战性,其生物学意义仍不清楚。我们开发了一种新的评分系统,将 TB 和 PDC 纳入一个单一参数(“综合评分”;CS),消除了对这种界限的需求,并允许同时捕获 PDC 和 TB 的预后价值。在一个 481 例 I-III 期 CRC 切除的队列中,CS 与美国癌症联合委员会(AJCC)分期、T 分期、N 分期、组织学分级、肿瘤沉积、血管淋巴管侵犯和神经周围侵犯显著相关(P <0.0001)。此外,CS 与 5 年无复发生存率、总生存率和疾病特异性生存率的降低显著相关(P <0.0001)。TB 和 PDC 与肿瘤学结果具有相似的相关性,风险比始终低于 CS。CS 与肿瘤学结果的相关性在按 AJCC 分期、解剖部位(直肠/结肠)和新辅助治疗状态分层的亚组分析中仍然显著。在多变量分析中,CS 保留了与无复发生存率、疾病特异性生存率和总生存率显著相关的意义(P =0.0002、0.005 和 0.009)。总之,CS 为 CRC 提供了强有力的风险分层,其与单独评估的 TB 和 PDC 相当。如果在其他地方得到验证,CS 具有实用优势和生物学原理,使其成为评估这些特征的一种有吸引力的替代方法。